aTyr Pharma Announces Presentations at The World Muscle Congress and 10th International Symposium on Aminoacyl-tRNA Synthetases (AARS2015)

September 24, 2015

SAN DIEGO, Sept. 24, 2015 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced participation in two upcoming international scientific conferences:

International World Muscle (WMS) Congress 2015, Brighton, UK

September 30 – October 4, 2015

- *Resolaris, a potential therapeutic for rare myopathies with an immune component.*
  (Guided Poster Session 1- October 1; 14:30-16:00 GMT)
  - Author and Presenter: Dr. John McKew, VP Research, aTyr Pharma
  - Supporting Authors: M. Ashlock, K. Ogilvie, L. Nangle, K. Taylor, K. Chiang, E. Mertsching, J. Chang, K. Moldt, C. Polizzi, Z. Xu, C. Lo, C. Lau, R. Adams, E. Chong

10th Annual International Symposium on Aminoacyl-tRNA Synthetases (AARS2015), Barcelona, Spain
October 18 – 22, 2015

- *Utilizing "Omics" to Unlock Aminoacyl-tRNA Synthetase Therapeutic Potential.*
  (Session V: Pharma & Biotech- October 21; 14:20-16:00 CEST)
  - Author and Presenter: Dr. Leslie Nangle, Associate Director, Discovery Biology, aTyr Pharma
  - Supporting Authors: R. Adams, K. Chiang, Y. Chong, W. Lo, Z. Xu, X. Yang, J. McKew, P. Schimmel, J. Mendlein

About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris™ is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD). Trials are planned in additional indications, including early onset FSHD and limb-girdle muscular dystrophy (LGMD) 2B. Trials are also planned for indications in interstitial lung disease (ILD). To protect this pipeline, aTyr built an intellectual property estate comprising 45 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.

SOURCE aTyr Pharma, Inc.

For further information: Marcy Graham, Vice President, Investor Relations & Corporate Communications, mgraham@atyrpharma.com, 858-223-1163, or Jessi Colund, Feinstein Kean Healthcare, jessi.colund@fkhealth.com, 952-649-8600